Epigenetic Therapeutics: Global Markets

This report is a comprehensive study of the global market for epigenetic therapeutics. It describes the epigenetic therapeutics market, which is segmented by product type and region. Based on product type, the market is segmented into PRAP inhibitors, Kinase inhibitors, IDH inhibitors, HDAC inhibitors, DNMT inhibitors and KMT inhibitors. The market is segmented by region into North America, Latin America, Europe, Asia-Pacific, and the Rest of the World (RoW).

This report examines the factors driving growth in the epigenetic drugs market, and it reviews major players, established companies and new entrants.

This report, however, does not cover epigenetic diagnostic assays and instruments.

Report Includes

77 tables
A comprehensive overview of the global markets for epigenetic therapeutics
Analyses of the global market trends with historical market revenue data (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
Understanding of the upcoming market potential for epigenetic therapeutics with an emphasis on new products and technologies, and areas of focus to forecast this market into various segments and sub-segments
Estimation of the actual market size and revenue forecast for the global epigenetic therapeutics market, and corresponding market share analysis product type and region
In-depth information (facts and figures) concerning major market dynamics (DROs), technology advancements, new products and applications in epigenomics, and COVID-19 impact on the industry
Coverage of the technological, economic, and business considerations of the market for epigenetic therapeutics, with analyses and growth forecasts through 2028
A look at the recent breakthrough innovations, key technological issues, market regulations, and current status on the intellectual property rights on epigenetic therapeutics
Review of patent trends and research publications for innovations in the genome-editing technologies
Insight into the recent industry structure, government regulations and policies, development issues, and the vendor landscape
Analysis of the competitive environment and market opportunities based on the company’s business strategies, product mapping, and operational integration
Descriptive company profiles of the leading pharma corporations, including AstraZeneca, Bristol-Myers Squibb, GSK, Ipsen, Seagen, and Incyte

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
Methodology
Information Sources
Geographic Breakdown
Analyst's Credentials
Custom Research
Related Research Reports

Chapter 2 Summary and Highlights

Highlights of the Market for Epigenetic Therapeutics

Chapter 3 Market Overview and Definitions

Overview
Epigenetics

Chapter 4 Market Trends

Market Drivers
Aging Population
Risk of Cancer in Major Countries
Penetration of Targeted Medicine in Emerging Markets
Market Opportunity
Market Restraints

Chapter 5 Market Breakdown by Product Type

Introduction
Prap Inhibitors
Kinase Inhibitors
Idh Inhibitors
Hdac Inhibitors
Dnmt Inhibitors
Kmt Inhibitors

Chapter 6 Impact of Covid-19

Introduction
Impact of Covid-19 on the Medical Devices and Pharmaceutical Industries
Decline/Delay in Elective Procedures
Impact of Covid-19 on Medical Device and Pharmaceutical Product Segments
Impact of Covid-19 on Epigenetic Therapeutics Markets

Chapter 7 Market Breakdown by Region

Market Overview and Discussion
North America
Latin America
Europe
Asia-Pacific
Rest of the World

Chapter 8 Emerging/Upcoming Technologies

Crispr
Antibody Drug Conjugates
Multitargeting Agents

Chapter 9 Competitive Landscape

Industry Scenario
Company Shares

Chapter 10 Patent Analysis

Patent Analysis, by Manufacturer

Chapter 11 Pipeline Analysis

Clinical Trials Scenario

Chapter 12 Company Profiles

Astrazeneca
Bristol-Myers Squibb
Clovis Oncology
Gsk plc
Incyte
Ipsen
Seagen
Servier Laboratories, Ltd.

Chapter 13 Appendix: Acronyms

List of Tables

Summary Table: Global Epigenetic Therapeutics Market, by Product Type, Through 2028
Table 1: Global Population, Age 60 and Older, 2010-2050
Table 2: Incidence of Pancreas Cancer, 2020-2040
Table 3: Incidence of Trachea, Bronchus and Lung Cancer, 2020-2040
Table 4: Incidence of Melanoma Cancer, 2020-2040
Table 5: Incidence of Prostate Cancer, 2020-2040
Table 6: Incidence of Breast Cancer, 2020-2040
Table 7: Incidence of Kidney and Renal Pelvis Cancers, 2020-2040
Table 8: Incidence of Hodgkin Lymphoma Cancer, 2020-2040
Table 9: Incidence of Non-Hodgkin Lymphoma Cancer, 2020-2040
Table 10: Incidence of Multiple Myeloma and Immunoproliferative Diseases, 2020-2040
Table 11: Incidence of Leukemia Cancer, 2020-2040
Table 12: Global Epigenetic Therapeutics Market, by Product Type, Through 2028
Table 13: Global PRAP Inhibitors Market, by Region, Through 2028
Table 14: Global Kinase Inhibitors Market, by Region, Through 2028
Table 15: Global IDH Inhibitors Market, by Region, Through 2028
Table 16: Global HDAC Inhibitors Market, by Region, Through 2028
Table 17: Global DNMT Inhibitors Market, by Region, Through 2028
Table 18: Global KMT Inhibitors Market, by Region, Through 2028
Table 19: Global Epigenetic Therapeutics Market, by Region, Through 2028
Table 20: North American Epigenetic Therapeutics Market, by Country, Through 2028
Table 21: Latin American Epigenetic Therapeutics Market, by Country, Through 2028
Table 22: European Epigenetic Therapeutics Market, by Country, Through 2028
Table 23: Asia-Pacific Epigenetic Therapeutics Market, by Country, Through 2028
Table 24: RoW Epigenetic Therapeutics Market, Through 2028
Table 25: Patents on Epigenetic Drugs, 2015-April 2023
Table 26: Selected Manufacturer Patents on Epigenetic Drugs, 2015-April 2023
Table 27: Patents on HDAC Inhibitors, 2015-April 2023
Table 28: Selected Manufacturer Patents on HDAC inhibitors, 2015-April 2023
Table 29: Patents on Kinase inhibitors, 2015-April 2023
Table 30: Patents on Verinostat Drug, 2015-April 2023
Table 31: Selected Manufacturer Patents on Verinostat Drug, 2015-April 2023
Table 32: Patents on Romidepsin Drug, 2015-April 2023
Table 33: Selected Manufacturer Patents on Romidepsin Drug, 2015-April 2023
Table 34: Patents on Panobinostat Drug, 2015-April 2023
Table 35: Selected Manufacturer Patents on Panobinostat Drug, 2015-April 2023
Table 36: Patents on Belinostat, 2015-April 2023
Table 37: Selected Manufacturer Patents on Belinostat, 2015-April 2023
Table 38: Patents on Tucidinostat Drug, 2015-April 2023
Table 39: Selected Manufacturer Patents on Tucidinostat Drug, 2015-April 2023
Table 40: Patents on 5-Azacytidine Drug, 2015-April 2023
Table 41: Selected Manufacturer Patents on 5-Azacytidine Drug, 2015-April 2023
Table 42: Patents on 5-Aza-2’-Deoxycytidine Drug, 2015-April 2023
Table 43: Selected Manufacturer Patents on 5-Aza-2’-Deoxycytidine Drug, 2015-April 2023
Table 44: Patents on Pinometostat Drug, 2015-April 2023
Table 45: Selected Manufacturer Patents on Pinometostat Drug, 2015-April 2023
Table 46: Patents on Ruxolitinib Drug, 2015-April 2023
Table 47: Selected Manufacturer Patents on Ruxolitinib Drug, 2015-April 2023
Table 48: Patents on AZD1152 Drug, 2015-April 2023
Table 49: Selected Manufacturer Patents on AZD1152 Drug, 2015-April 2023
Table 50: Patents on Olaparib Drug, 2015-April 2023
Table 51: Selected Manufacturer Patents on Olaparib Drug, 2015-April 2023
Table 52: Patents on Veliparib Drug, 2015-April 2023
Table 53: Selected Manufacturer Patents on Veliparib Drug, 2015-April 2023
Table 54: Patents on Niraparib Drug, 2015-April 2023
Table 55: Selected Manufacturer Patents on Niraparib Drug, 2015-April 2023
Table 56: Patents on Rucaparib Drug, 2015-April 2023
Table 57: Selected Manufacturer Patents on Rucaparib Drug, 2015-April 2023
Table 58: Patents on Talazoparib Drug, 2015-April 2023
Table 59: Selected Manufacturer Patents on Talazoparib Drug, 2015-April 2023
Table 60: Selected Kinase Inhibitors in Clinical Trials, as of 2023
Table 61: Selected Olaparib Inhibitors in Clinical Trials, as of 2023
Table 62: Selected Romidepsin Inhibitors in Clinical Trials, as of 2023
Table 63: Selected Ruxolitinib Inhibitors in Clinical Trials, as of 2023
Table 64: AstraZeneca: Company Annual Revenue, 2019-2022
Table 65: AstraZeneca: Annual Revenue, by Product, 2022
Table 66: Bristol-Myers Squibb: Company Annual Revenue, 2019-2022
Table 67: Clovis Oncology: Revenue, 2019-2021
Table 68: GSK: Company Annual Revenue, 2019-2022
Table 69: GSK: Annual Revenue, by Product, 2022
Table 70: Incyte: Company Annual Revenue, 2019-2021
Table 71: Incyte: Product Revenue, 2019-2021
Table 72: Ipsen: Sales Revenue, 2021 and 2022
Table 73: Ipsen: Sales Revenue, by Segment, 2021 and 2022
Table 74: Ipsen: Sales Revenue, by Region, 2021 and 2022
Table 75: Seagen: Company Annual Revenue, 2019-2021
Table 76: Acronyms Used in this Report

List of Figures

Summary Figure A: Global Epigenetic Therapeutics Market, by Product Type, 2019-2028
Summary Figure B: Global Epigenetic Therapeutics Market Share, by Product Type, 2022
Figure 1: Global Epigenetic Therapeutics Market, by Product, 2020-2028
Figure 2: Global Epigenetic Therapeutics Market Share, by Product, 2022
Figure 3: Global PRAP Inhibitors Market, by Region, 2020-2028
Figure 4: Global PRAP Inhibitors Market Share, by Region, 2022
Figure 5: Global Kinase Inhibitors Market, by Region, 2020-2028
Figure 6: Global Kinase Inhibitors Market Share, by Region, 2022
Figure 7: Global IDH Inhibitors Market, by Region, 2020-2028
Figure 8: Global IDH Inhibitors Market Share, by Region, 2022
Figure 9: Global HDAC Inhibitors Market, by Region, 2020-2028
Figure 10: Global HDAC Inhibitors Market Share, by Region, 2022
Figure 11: Global DNMT Inhibitors Market, by Region, 2020-2028
Figure 12: Global DNMT Inhibitors Market Share, by Region, 2022
Figure 13: Global KMT Inhibitors Market, by Region, 2020-2028
Figure 14: Global KMT Inhibitors Market Share, by Region, 2022
Figure 15: Global Epigenetic Therapeutics Market Share, by Region, 2022
Figure 16: North American Epigenetic Therapeutics Market Share, by Country, 2022
Figure 17: Latin American Epigenetic Therapeutics Market Share, by Country, 2022
Figure 18: European Epigenetic Therapeutics Market Share, by Country, 2022
Figure 19: Asia-Pacific Epigenetic Therapeutics Market Share, by Country, 2022
Figure 20: Global Epigenetic Therapeutics Market Share, by Company, 2022
Figure 21: Global PRAP Inhibitors Market Share, by Company, 2022
Figure 22: Global Kinase Inhibitors Market Share, by Company, 2022
Figure 23: Global IDH Inhibitors Market Share, by Company, 2022
Figure 24: Global HDAC Inhibitors Market Share, by Company, 2022
Figure 25: Global DNMT Inhibitors Market Share, by Company, 2022
Figure 26: Global KMT Inhibitors Market Share, by Company, 2022
Figure 27: AstraZeneca: Sales Share, by Product, 2022
Figure 28: AstraZeneca: Sales Share, by Region, 2022
Figure 29: Bristol-Myers Squibb: Sales Share, by Region, 2022
Figure 30: GSK: Revenue Share, by Product, 2022
Figure 31: GSK: Sales Share, by Region, 2022
Figure 32: Ipsen: Sales Revenue Share, by Segment, 2022
Figure 33: Ipsen: Sales Revenue Share, by Region 2022

Executive Summary

The global epigenetic therapeutics market was valued at $6.4 billion in 2022. The market is expected to reach $9.8 billion by 2028, growing at a compound annual growth rate (CAGR) of 7.7% over the forecast period. Growth factors include aging populations, increased frequency of cancer risk associated with aging and increased prevalence of cancers cases such as acute-T-cell leukemia, breast cancer, ovarian cancer, Non-Small-Cell lung cancers. Epigenetic drug therapy serves as an ultimate treatment option when a cancer patient is not responding to the conventional therapies such as chemotherapy.

Technological innovations in epigenetic drug discovery and development are driving increased use of epigenetic therapeutics, which also is pushing market growth. However, loss of exclusivity in the case of a few branded drugs and the entry of generic drugs into the market is the restraining the growth of this market.

In 2022, the PRAP inhibitors segment held the largest share of the global market for epigenetic therapeutics, with 51.7% of the market, followed by Kinase inhibitors (37.5%), HDAC inhibitors (5.8%), IDH inhibitors (2.8%), DNMT inhibitors (1.9%) and KMT inhibitors (0.2%)

Companies Mentioned

Astrazeneca
Bristol-Myers Squibb
Clovis Oncology
Gsk plc
Incyte
Ipsen
Seagen
Servier Laboratories, Ltd.

Table Information

Report Attribute	Details
No. of Pages	155
Published	June 2023
Forecast Period	2023 - 2028
Estimated Market Value ( USD ) in 2023	$ 6.8 Billion
Forecasted Market Value ( USD ) by 2028	$ 9.8 Billion
Compound Annual Growth Rate	7.7%
Regions Covered	Global
No. of Companies Mentioned	8

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5232EUR$5,500USD£4,404GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€6278EUR$6,600USD£5,285GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7534EUR$7,920USD£6,342GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€9040EUR$9,504USD£7,610GBP

Report Includes

Table of Contents

Executive Summary

Companies Mentioned

Table Information

Related Topics

Related Reports

Epigenetic Drug and Diagnostic Technology Market Report: Trends, Forecast and Competitive Analysis to 2030

Epigenetics Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

Epigenetic Regulation of Cancer - Part A. International Review of Cell and Molecular Biology Volume 380

Epigenetics Global Market Report 2024

Epigenetics Market by Product, Technique, Methods, Application, End User - Global Forecast 2025-2030